Hyperphosphatemia as a potential risk factor for arteriovenous fistula dysfunction: A retrospective study in hemodialysis patients

TL;DR

This study finds that high phosphate levels in the blood are linked to a higher risk of arteriovenous fistula dysfunction in hemodialysis patients.

Contribution

The study identifies hyperphosphatemia as an independent risk factor for arteriovenous fistula dysfunction using multivariate analysis and nonlinear modeling.

Findings

Hyperphosphatemia significantly correlates with arteriovenous fistula dysfunction (P = 0.0052).

High phosphorus levels are an independent risk factor for AVF dysfunction (P for trend < 0.001).

A nonlinear relationship exists between phosphorus levels and AVF dysfunction with a cutoff at 1.544 mmol/L.

Abstract

The study investigates the relationship between Hyperphosphatemia and arteriovenous fistula dysfunction in patients undergoing maintenance hemodialysis.

Data were collected from patients who had their first arteriovenous fistula creation and regular maintenance hemodialysis between 2019 and 2023. Patients were divided into four groups based on serum phosphorus levels (<1.33 mmol/L, 1.33–1.61 mmol/L, 1.61–1.965 mmol/L, > 1.965 mmol/L). Statistical methods included Kaplan-Meier survival curves, Cox proportional hazards regression models, and Restricted Cubic Spline.

The study included 239 patients. Kaplan-Meier survival curves showed that Hyperphosphatemia significantly correlated with arteriovenous fistula dysfunction (P = 0.0052). Cox univariate analysis showed phosphorus (HR = 3.16, P < 0.001) is risk factor of arteriovenous fistula dysfuntion. Multivariate Cox regression analysis further confirmed high phosphorus levels were an independent risk factor of AVF dysfuntion (P for trend<0.001). Restricted Cubic Spline showed a nonlinear relationship between phosphorus levels and arteriovenous fistula dysfunction (P for non-linearity = 0.024), with a cutoff point at 1.544 mmol/L (LR = 0.035).

Hyperphosphatemia is an independent risk factor for arteriovenous fistula dysfunction, emphasizing the need for clinical practice to pay attention to the impact of mineral metabolism disorders on the integrity of arteriovenous fistula and to strengthen phosphate management.

Figures